Clinical Trial Update: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating teclistamab monotherapy against PVd or Kd in relapsed or refractory multiple myeloma; study status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Kyprolis (carfilzomib)
• Pomalyst (pomalidomide)
• TECVAYLI (TECLISTAMAB-CQYV)
• Velcade (bortezomib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING